Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Han L, et al. Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23. Haematologica. 2020. PMID: 31123034 Free PMC article.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: koller p. Am J Hematol. 2020 Oct;95(10):1193-1199. doi: 10.1002/ajh.25929. Epub 2020 Jul 28. Am J Hematol. 2020. PMID: 32628327 Free article.
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, Ali H, Koller P, Arslan S, Budde E, Khaled S, Dadwal S, Snyder DS, Artz A, Forman S, Nakamura R, Stein A, Marcucci G, Aldoss I, Pullarkat V. Salhotra A, et al. Among authors: koller p. Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8. Am J Hematol. 2021. PMID: 33719090 Free article. No abstract available.
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation.
Mac S, Ngo D, Yang D, Chen J, Ali H, Arslan S, Dadwal S, Salhotra A, Cao T, Karras N, Aldoss I, Koller P, Artz A, Aribi A, Sandhu K, Pullarkat V, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Mac S, et al. Among authors: koller p. Bone Marrow Transplant. 2021 Oct;56(10):2464-2470. doi: 10.1038/s41409-021-01364-0. Epub 2021 Jun 9. Bone Marrow Transplant. 2021. PMID: 34108676
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Koller P, Ball B, Stewart F, Curtin P, Artz A, Nakamura R, Marcucci G, Forman SJ, Stein AS, Pullarkat V. Aldoss I, et al. Among authors: koller p. Cancer. 2022 Feb 1;128(3):529-535. doi: 10.1002/cncr.33967. Epub 2021 Oct 11. Cancer. 2022. PMID: 34633671 Free article.
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Salhotra A, Tsai NC, Zhang J, Ngo D, Aribi A, Sandhu K, Ball B, Al-Malki M, Ali H, Koller P, Artz A, Forman S, Nakamura R, Stein A, Marcucci G, Aldoss I, Pullarkat V. Salhotra A, et al. Among authors: koller p. Br J Haematol. 2022 Mar;196(6):e71-e74. doi: 10.1111/bjh.17996. Epub 2021 Dec 21. Br J Haematol. 2022. PMID: 34931310 No abstract available.
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Ball BJ, et al. Among authors: koller p. Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10. Leuk Lymphoma. 2022. PMID: 36089918 No abstract available.
140 results